Proceedings of the National Academy of Sciences · 2017 · 129 citations · 34 references
Life SciencesNeurobiologyNeuroscienceMolecular NeuroscienceNeurodegenerationNeuropharmacologyAlzheimer DiseaseAmyloid FormationNeurodegeneration MechanismsNeurodegenerative DiseasesNeurodegenerative DisordersNeuroprotectionAmyloid Beta AggregationAmyloid Beta PeptidesAmyloid Beta PlaquesAmyloid Beta-targeted TherapyAmyloid InhibitionAmyloid PlaquesBeta Secretase InhibitionInhibition Of Amyloid Formation
Significance The accumulation of amyloid-β (Aβ) proteins in the brain contributes to Alzheimer´s disease (AD). Reducing Aβ by inhibiting its production with a β-secretase (BACE) inhibitor represents a novel mechanism for treating AD; however, whether this therapeutic strategy is capable of repairing impaired brain circuits associated with AD is unknown. Here we demonstrate that BACE inhibition is beneficial to all levels of impairment in an AD mouse model: cellular, long-range circuitry, and memory. We provide evidence that the rescue is dependent on the reduction of soluble forms of Aβ surrounding amyloid plaques. These results have mechanistic and therapeutic implications for AD, including Aβ-related memory defects.
34
Amyloid Oligomers Exacerbate Tau Pathology in a Mouse Model of Tauopathy
Maj-Linda B. Selenica, Milene L. Brownlow, Jeffy P. Jimenez et al. · Neurodegenerative Diseases · 2012 · 10.4K citations · Full text
Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease
Stephen Salloway, Reisa A. Sperling, Nick C. Fox et al. · New England Journal of Medicine · 2014 · 2K citations · Full text
Medicine, Neurology, Pharmacology +17